The next focusIR Investor Webinar takes places on 14th May with guest speakers from Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 12,050.00
Bid: 12,038.00
Ask: 12,040.00
Change: -106.00 (-0.87%)
Spread: 2.00 (0.017%)
Open: 12,092.00
High: 12,178.00
Low: 12,010.00
Prev. Close: 12,156.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

UPDATE 4-Ignoring WHO call, major nations stick to vaccine booster plans

Thu, 05th Aug 2021 09:09

* Global body disapproves of boosters until more people
vaccinated

* Some rich nations going ahead anyway to fend off Delta
variant

* Elderly and vulnerable to benefit first from booster shots

* Low-income nations suffer from lack of vaccine supplies
(Adds more remarks from Israeli PM, paras 7-8)

By Sudip Kar-Gupta and Caroline Copley

PARIS/BERLIN, Aug 5 (Reuters) - Germany, France and Israel
will go ahead with plans to administer COVID-19 vaccine
boosters, disregarding an appeal by the World Health
Organisation to hold off until more people are vaccinated around
the world.

The decision to press ahead with booster shots despite the
WHO's strongest statement yet highlights the huge inequities in
responses to the pandemic as richer nations ramp up programmes
to protect citizens from the more infectious Delta variant.

French President Emmanuel Macron said France was working on
rolling out third doses to the elderly and vulnerable from
September.

Germany intends to give boosters to immunocompromised
patients, the very elderly and nursing home residents from
September, the health ministry said.

Israeli Prime Minister Naftali Bennett in a statement urged
older citizens to get a third shot after the government last
month kicked off a campaign to give booster doses.

"Whoever is over the age of 60, and has yet to receive the
third dose of the vaccine, is six times more susceptible to
severe illness and - heaven forbid - death," Bennett said.

In an online discussion with the public and journalists,
Bennett said Israel's drive to give third doses of the
Pfizer/BioNTech vaccine to people over 60 would provide vital
information to the world on combating the Delta variant.

Israel, with a population of 9.3 million, was a small
country whose vaccine use "doesn't really affect the world
supply significantly", he added.

WHO chief Tedros Adhanom Ghebreyesus called on Wednesday for
a halt to boosters until at least the end of September, saying
it was unacceptable for rich countries to use more of the global
vaccine supply.

INEQUALITIES MOUNT

High-income countries administered around 50 doses for every
100 people in May, and that number has since doubled, according
to WHO. Low-income countries have only been able to administer
1.5 doses for every 100 people, due to lack of supplies.

"I understand the concern of all governments to protect
their people from the Delta variant. But we cannot accept
countries that have already used most of the global supply of
vaccines using even more of it," Tedros said.

Germany rejected those accusations, saying it would also
donate at least 30 million vaccine doses to poorer countries.

"We want to provide the vulnerable groups in Germany with a
precautionary third vaccination and at the same time support the
vaccination of as many people in the world as possible," the
health ministry said.

Following Tedros' comments, the White House said on
Wednesday it was prepared to provide booster shots if needed,
suggesting it would not heed the WHO's call either.

Pfizer has said boosters are most likely needed due
to waning antibody responses, particularly after six months.

U.S. health regulators have said that more scientific
evidence is needed to be certain boosters are needed, but have
indicated they believe a third shot may be needed for people
with compromised immune systems.

Macron's government is trying to step up France's
vaccination programme as the country faces a fourth wave of the
virus and street demonstrations in protest against the
government's COVID policies.

France and Germany have so far given at least one dose of a
COVID-19 vaccine to 64.5% and 62% of their respective
populations, with 49% of the French and 53% of Germans fully
vaccinated.

(Reporting by Sudip Kar-Gupta and Nicolas Delame in Paris,
Alexander Ratz and Caroline Copley in Berlin, Jeffrey Heller in
Jerusalem; Editing by Nick Macfie, Josephine Mason, Andrew
Cawthorne, William Maclean)

More News
3 May 2024 12:17

CORRECT: Angle shares up on assay development deal with AstraZeneca

(Correcting company name in headline)

Read more
3 May 2024 11:50

Angle shares up on assay development deal with AstraZenaca

(Alliance News) - Shares in Angle PLC jumped on Friday, after the company said it has been chosen to develop a prostate cancer assay using its Parsortix technology, opening the door for future clinical study-supporting contracts.

Read more
3 May 2024 07:50

LONDON BRIEFING: InterContinental Hotels makes first-quarter progress

(Alliance News) - London's FTSE 100 is called to open higher on Friday, on the expectation of a softer US jobs report, which could take some sting out of hawkish Federal Reserve interest rate expectations.

Read more
2 May 2024 10:04

AstraZeneca notes positive trial results for Calquence treatment

(Alliance News) - AstraZeneca PLC on Thursday said it observed positive high-level results in the Echo phase 3 trial of its Calquence treatment for previously untreated adult patients with mantle cell lymphoma.

Read more
2 May 2024 07:45

AstraZeneca reports positive results from blood cancer drug trial

(Sharecast News) - AstraZeneca has reported positive results from the use of its Calquence drug in a clinical trial to treat a rare type of blood cancer.

Read more
29 Apr 2024 22:52

J&J, Bristol Myers lose challenges to US drug price negotiation program

April 29 (Reuters) - A U.S. judge on Monday rejected a challenge by Bristol Myers Squibb and Johnson & Johnson to a law requiring them to negotiate the prices of their blockbuster blood clot prevention drugs with the U.S government's Medicare health insurance program or pay heavy penalties.

Read more
29 Apr 2024 10:02

LONDON BROKER RATINGS: Deutsche Bank likes Frasers; Barclays cuts JD

(Alliance News) - The following London-listed shares received analyst recommendations Monday morning and Friday:

Read more
29 Apr 2024 09:13

AstraZeneca makes progress with Truqap and Enhertu cancer treatments

(Alliance News) - AstraZeneca PLC on Monday said its Truqap drug has been recommended for approval in the EU to treat a form of breast cancer, while also noting trial results for its Enhertu offering.

Read more
29 Apr 2024 07:50

LONDON BRIEFING: Hipgnosis Songs Fund backs new Blackstone bid

(Alliance News) - London's FTSE 100 is called to open higher on Monday, with heady gains for US tech stocks on Friday brightening the mood in Europe and Asia at the start of the new week.

Read more
29 Apr 2024 07:24

AstraZeneca makes progress with two breast cancer treatments

(Sharecast News) - AstraZeneca issued favourable updates on two of its breast cancer treatments on Monday - 'Truqap', or capivasertib, and 'Enhertu', or trastuzumab deruxtecan - following encouraging results from respective phase three trials.

Read more
26 Apr 2024 09:33

LONDON BROKER RATINGS: Peel Hunt cuts ConvaTec to 'reduce'

(Alliance News) - The following London-listed shares received analyst recommendations Friday morning:

Read more
25 Apr 2024 16:57

LONDON MARKET CLOSE: FTSE 100 shakes off red-hot US inflation gauge

(Alliance News) - London's FTSE 100 outperformed on Thursday, enjoying a solid rise on largely well-received corporate earnings and a share price jump for miner Anglo American after it received a takeover bid from peer BHP.

Read more
25 Apr 2024 15:14

London close: Stocks finish mixed as US GDP growth slows

(Sharecast News) - London's stock markets finished with a mixed performance on Thursday, as investors digested a slower-than-expected GDP growth reading from the United States, while a slew of well-received earnings underpinned the top-flight index.

Read more
25 Apr 2024 11:50

LONDON MARKET MIDDAY: FTSE 100 hits high on offer for Anglo American

(Alliance News) - The FTSE 100 was outperforming European markets at midday on Thursday, with the index boosted to a record high thanks to takeover talks.

Read more
25 Apr 2024 10:33

AstraZeneca leaps after smashing first-quarter forecasts

Q1 revenue up 19% to $12.68 bln

*

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.